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Background: The aim of this study was to investigate the effects of Rikkunshito on ghrelin 
secretion and on cisplatin-induced anorexia in humans.
Methods: The study was performed as a crossover design, and ten unresectable or relapsed 
gastric cancer patients were randomly divided into two groups. Group A (n = 5) was started on 
Rikkunshito (2.5 g three times daily, orally) from the first course of chemotherapy and followed 
by a second course without Rikkunshito. A treatment with reversed order was performed for 
Group B (n = 5). All patients received combined chemotherapy with S-1 plus cisplatin. The 
primary endpoint was the amount of oral intake, and the categories of scales of anorexia, nausea, 
and vomiting; secondary endpoints included the plasma concentration of acylated ghrelin.
Results: In the Rikkunshito-on period, no decrease of the plasma concentration of acylated 
ghrelin induced by cisplatin was observed. The average oral intake in the Rikkunshito-on period 
was significantly larger than that in the Rikkunshito-off period, and the grade of anorexia was 
significantly lower in the Rikkunshito-on period than in the Rikkunshito-off period.
Conclusion: Rikkunshito appeared to prevent anorexia induced by cisplatin, resulting in 
effective prophylactic administration of chemotherapy with cisplatin, and patients could   continue 
their treatments on schedule.
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Introduction
Combined chemotherapy with S-1 plus cisplatin is an attractive chemotherapy regimen 
for gastric cancer. A previous Phase I/II trial of this regimen in metastatic gastric cancer 
reported a high response rate of 76% and acceptable toxicity.1 Recently, a Phase III 
Japanese trial of chemotherapeutic regimens for metastatic gastric cancer (SPIRITS 
trial) demonstrated that S-1 plus cisplatin led to significantly longer median overall 
survival than S-1 alone (13 months versus 11 months).2 Cisplatin is widely used in 
various chemotherapies, but undesirable side effects, such as nausea, vomiting, and 
anorexia, markedly affect the quality of life of patients and may make the continuation 
of chemotherapy difficult. While some antiemetic agents have been introduced as 
treatment for nausea and vomiting,3,4 appetite loss is still present in many cancer 
patients. However, the mechanism of the resulting appetite loss during chemotherapy 
is not thoroughly understood.
Ghrelin is an endogenous ligand of the growth hormone secretagogue receptor; 
it consists of 28 amino acids and is secreted mainly from the stomach.5 Ghrelin is 
known to have an intense appetite-enhancing effect in addition to a growth hormone 
secretion-promoting effect.6 Ghrelin is the only hormone that exhibits an orexigenic Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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effect following peripheral administration.7 In addition, 
ghrelin exhibits a variety of actions, including stimulation of 
growth hormone secretion, gastric motility, and gastric acid 
secretion,8 as well as induction of a positive energy balance.9 
The level of plasma ghrelin is thought to be related to gas-
trointestinal disorders, and ghrelin has been administered to 
patients with anorexia-related disorders as a new therapy.10 
However, the intravenous and repeated administration of 
ghrelin presented a considerable burden for the patients.
Rikkunshito, a traditional Japanese medicine, is used to 
treat various gastrointestinal tract disorders, such as functional 
dyspepsia, gastroesophageal reflux, dyspeptic symptoms of 
post-gastrointestinal surgery, and chemotherapy-induced 
nausea.11–13 Takeda et al14 showed that a flavonoid in 
  Rikkunshito suppressed a cisplatin-induced decrease 
in plasma acylated ghrelin levels and increased food intake 
in rats, and was mediated by serotonin (5-HT2B and 5-HT2C) 
receptors. The aim of this study was to investigate the effect 
of Rikkunshito on ghrelin secretion and on cisplatin-induced 
anorexia in humans.
Materials and methods
Patient eligibility
Eligible patients had histologically proved unresectable 
or recurrent gastric cancer. Up to one regimen of prior 
  chemotherapy was allowed (adjuvant chemotherapy was 
allowed provided that at least 28 days had elapsed since the 
last treatment), except for prior treatment with cisplatin.
Other inclusion criteria were as follows: age 20–75 years; 
Eastern Clinical Oncology Group performance status 0–1; 
estimated life expectancy more than 3 months; a white 
blood cell count between 4000 and 12,000 mm3; an absolute 
neutrophil count of over 2000 mm3, a   platelet count of over 
100,000 mm3, and a hemoglobin level of over 8.0 g/dL; 
aspartate aminotransferase and alanine aminotransferase 
levels within two times the upper limit of normal for the 
institution; serum bilirubin level less than 1.5 mg/dL; serum 
creatinine level within the upper limit of the normal value for 
the institution; 24-hour creatinine clearance more than 50 mL/
minute; and a normal electrocardiogram. Only patients who 
could swallow tablets were eligible. Patients were excluded 
if they had brain metastases, severe comorbid conditions, 
active double cancers, or a past history of drug allergy or were 
unable to comply with the protocol requirements. Pregnant 
women were also excluded.   Written informed consent was 
obtained from all patients before study entry.
Treatment design
The study was performed as a crossover design because of 
the limited number of patients (Figure 1). Ten patients were 
randomly divided into two groups. The gender, age, tumor 
characteristics, and performance status of these 10 patients 
are listed in Table 1. Group A (n = 5) was started on 
  Rikkunshito from the first course of chemotherapy followed 
by a second course of chemotherapy without Rikkunshito. 
Treatment with reversed order was performed for Group B 
(n = 5). Patients in the intervention period took Rikkunshito 
(Tsumura Co, Ltd, Tokyo, Japan) at a daily dose of 7.5 g 
(2.5 g three times daily, orally) before every meal through 
chemotherapy from days 1 to 21. On the other hand, patients 
in the control period took nothing. All patients received 
combined chemotherapy with S-1 plus cisplatin as follows. 
S-1 (Taiho Pharmaceutical Co, Ltd, Tokyo, Japan) was given 
orally twice daily after meals at a fixed dose of 80 mg/m2/
day for 21 consecutive days followed by a 14-day rest period; 
this cycle was repeated every 5 weeks. The dose of S-1, 
Rikkunshito
Group A
Group B
Cisplatin
S-1 S-1 Rest
Day 8 Day 21 Day 35 Day 8 Day 21 Day 35
Rest
S-1 S-1 Rest
Day 8 Day 21
Exam Exam
Exam Exam
Day 35 Day 8 Day 21 Day 35
Rest
Cisplatin Cisplatin
Cisplatin
Rikkunshito
Figure 1 Crossover study design. Patients in group A initially took oral rikkunshito before every meal for 3 weeks (on treatment). After a rest period of 2 weeks, rikkunshito 
was discontinued for 3 weeks (off treatment). Conversely, patients in group B initially were off treatment for 3 weeks and then on treatment for 3 weeks after the rest 
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decided on the basis of body surface area (BSA), was 80 mg 
(BSA ,1.25 m2), 100 mg (BSA 1.25–1.5 m2), or 120 mg 
(BSA 1.5 m2). Cisplatin (Landa™, Nippon Kayaku Co, 
Ltd, Tokyo, Japan) was administered intravenously on day 8. 
All patients received 16 mg of dexamethasone and 3 mg of 
granisetron intravenously one hour before cisplatin infusion 
and 8 mg of dexamethasone on days 9 and 10. The initially 
administered dose of cisplatin was 60 mg/m2. Blood samples 
were obtained from each patient before the administration 
of cisplatin on day 8 and 3 hours after the administration of 
cisplatin was finished. The primary endpoint was the amount 
of oral intake, and the categories of the scales of anorexia, 
nausea, and vomiting; secondary endpoints included the 
plasma concentration of acylated ghrelin.
Measurement of acylated ghrelin
The blood samples were collected before and 3 hours after 
the administration of cisplatin. The sample collecting time 
was determined on the basis of our unpublished experimental 
data from dogs. The plasma samples for acylated ghrelin 
were promptly centrifuged at 4°C, and the supernatants 
were acidified with 1 mol/L HCl (1/10 volume), frozen, and 
kept below 40°C until measurement. The acylated ghrelin 
level was determined using the active ghrelin enzyme-linked 
immunosorbent assay kit (SCETI Co, Ltd, Tokyo, Japan).
Definition of response
Following administration of cisplatin, each patient was 
hospitalized and monitored by direct observation and patient 
interview for 5 days. The amount of oral intake of each 
meal was observed and scored by 11 stages from 0 to 10 by 
nurses, and the average oral intake during 5 days was calcu-
lated and analyzed. Categories of the scales for anorexia, 
nausea, and vomiting were graded according to the National 
Cancer Institute common toxicity criteria, version 3.0.15 We 
defined the time to treatment failure as the period between 
the time that administration of cisplatin was finished and the 
time that vomiting or dry vomiting occurred or the time of 
administration of the antiemetic.
statistical analysis
The results were expressed as the mean ± the standard error 
of the mean. The Student’s t-test was used to test for the 
  significance of differences between groups. For the   comparison 
of time to treatment failure between two groups, the Kaplan-
Meier product-limit method and log-rank test were used. 
A P value ,0.05 was considered statistically significant. 
  Statistical calculations were performed using StatView® 
software (version 5.0, Abacus Concepts Inc, Berkeley, CA).
Results
Plasma concentration of acylated ghrelin
In the Rikkunshito-off period, the average concentration of 
plasma acylated ghrelin 3 hours after the administration of 
cisplatin decreased from that before administration of cis-
platin, but the difference was not significant. On the other 
hand, in the Rikkunshito-on period, no decrease in plasma 
concentration of acylated ghrelin was observed between 
before and after administration (Figure 2).
Amount of oral intake
The average oral intake in the Rikkunshito-on period was 
significantly larger than that in the Rikkunshito-off period 
(6.29 versus 3.94, P = 0.0496, Figure 3). This tendency was 
similarly seen in group A and group B, and neither an order 
effect nor a carry-over effect was seen.
Anorexia, nausea, vomiting
The grade of anorexia (0–4) was significantly lower in the 
Rikkunshito-on period than in the Rikkunshito-off period 
Table 1 Background of patients
Patient Age (years) Sex Tumor PS Group
1 55 M recurrent 1 A
2 61 F Unresectable 0 A
3 67 M recurrent 0 B
4 71 M Unresectable 0 A
5 52 M Unresectable 1 A
6 72 M recurrent 0 B
7 50 F Unresectable 1 B
8 62 M Unresectable 0 B
9 67 M recurrent 1 A
10 61 M Unresectable 0 B
Abbreviation: Ps, performance status.
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Figure 2 Plasma concentration of acylated ghrelin. in the rikkunshito-on period 
(rikkunshito  [+]),  no  decrease  of  plasma  concentration  of  acylated  ghrelin  was 
observed before and after administration. 
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(1.2   versus 2.2, P = 0.0441, Figure 4). No order effect or carry-
over effect was seen. The difference in the grade of nausea (0–3) 
was not significant, although the grade in the Rikkunshito-on 
period tended to be lower (Figure 5). The difference in grade 
of vomiting (0–4) was not significant (Figure 6).
Time to treatment failure
The number of cases of treatment failure in the Rikkunshito-
off period was nine, whereas that in the Rikkunshito-on 
period was five. However, the difference was not significant 
(Figure 7).
Toxicity
Pseudohyperaldosteronism and hepatic toxicity have been 
reported as side effects of Rikkunshito. We assessed hyper-
tension, edema, hypokalemia, and transaminitis. These 
events did not appear for either the Rikkunshito-on or the 
Rikkunshito-off period, and all patients were able to complete 
the examination.
Discussion
Ghrelin has been measured in patients with various diseases, 
for example, functional dyspepsia,16 breast cancer, colon 
cancer,17 and hepatocellular carcinoma,18 and the relation-
ship between the disease and the level of ghrelin has 
been assessed. Garcia et al19 reported that plasma ghrelin 
levels were higher in cachectic patients than in noncachectic 
ones, suggesting that an increase in the plasma ghrelin level 
might be related to secondary loss of appetite in patients. The 
plasma ghrelin level in patients with obesity was low, and 
the decrease in body weight was proportional to increasing 
ghrelin levels.20 The ghrelin level of patients with anorexia 
nervosa was reported to be high.21 It remains controversial 
whether the plasma ghrelin level of patients with   functional 
dyspepsia increases or decreases.22,23 Akamizu et al24 
  experimented with the administration of ghrelin in patients 
with functional dyspepsia; their results showed that daily food 
intake tended to increase in comparison with intake before 
and after completion of treatment. However, the difference 
was not significant. The hunger sensation was reported to 
be significantly elevated. It is certain that ghrelin is related 
to appetite; however, the manner in which it affects appetite 
and food intake remains unclear.
Rikkunshito is a traditional Japanese medicine (Kampo) 
that is widely used for treating upper gastrointestinal 
symptoms, such as decreased gastric motility after surgery11 
and chronic idiopathic dyspepsia,12 and its beneficial effects 
have been shown. Rikkunshito contains mixed raw herbs 
in the following ratios: JP Atractylodes lancea rhizome 
4.0 g, JP Ginseng 4.0 g, JP Pinellia tuber 4.0 g, JP Poria 
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Figure 3 Comparison of the amount of oral intake. The average oral intake in the 
Rikkunshito-on period was significantly larger than that in the Rikkunshito-off period.
Note: *P = 0.0496.
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Figure 4 Comparison of the grade of anorexia. The grade of anorexia (0–4) was 
significantly lower in the Rikkunshito-on period than in the Rikkunshito-off period.
Note: *P = 0.0441.
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Figure 5 Comparison of the grade of nausea. The difference in the grade of nausea 
(0–3) was not significant.
Abbreviation: NS, not significant.
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Figure 6 Comparison of the grade of vomiting. The difference in the grade of 
vomiting (0–4) was not significant.
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sclerotium 4.0 g, JP Jujube 2.0 g, JP Citrus unshiu peel 2.0 g, 
JP Glycyrrhiza 1.0 g, and JP Ginger 0.5 g. Rikkunshito has 
been approved for medicinal use by the Japanese Ministry 
of Health and Welfare, although the mechanism by which 
Rikkunshito alleviates upper gastrointestinal symptoms 
has not been clarified. Recently, Rikkunshito was used in 
combination with granisetron to alleviate the side effects 
of anticancer drugs, without affecting their efficacy.12 
Decreased gastric motility and decreased appetite as a result 
of surgery, anticancer drugs, and functional dyspepsia may 
be caused by a decreased plasma ghrelin level25,26 or ghrelin 
function. In clinical applications, Rikkunshito is particularly 
effective against functional dyspepsia,11 and its efficacy   
is also supported by basic research in rats with a delayed 
gastric emptying function.27 Matsumura et al28 reported that 
Rikkunshito significantly increased the plasma acylated 
ghrelin level in healthy volunteers and normal mice, and 
the ghrelin mRNA expression level in the stomach was 
upregulated in mice. These findings suggest the possibility 
that Rikkunshito affects the secretion or function of ghrelin.
Takeda et al14 reported that Rikkunshito suppresses a 
cisplatin-induced decrease in the plasma level of ghrelin, 
a hormone that stimulates gastrointestinal motility and 
food intake in rats. Heptomethoxyflavone, hesperidin, and 
isoliquiritigenin, the flavonoids in Rikkunshito, are reported 
to be responsible for a 5HT2B antagonistic effect and restora-
tion of the plasma level of ghrelin.
In the present study, in the Rikkunshito-off period, the 
average concentration of plasma acylated ghrelin after 
administration decreased from that before administration, 
but the difference was not significant. On the other hand, in 
the Rikkunshito-on period, a decrease of plasma concentra-
tion of acylated ghrelin was not observed before nor after 
administration (Figure 2). This result does not contradict 
the findings of Takeda et al. Rikkunshito might restore the 
plasma level of ghrelin.
The average oral intake in the Rikkunshito-on period was 
significantly larger than that in the Rikkunshito-off period 
(Figure 3), and the grade of anorexia was significantly lower 
in the Rikkunshito-on period than that in the Rikkunshito-off 
period (Figure 4). These results might also indicate the effect 
of restoration of ghrelin. On the other hand, the differences in 
the grade of nausea, vomiting, and time to treatment failure 
between the two groups were not significant (Figures 5, 6, 
and 7). Nausea and vomiting are reactions mainly related 
to 5HT3 receptors, and the relationship with ghrelin might 
be minimal.
In summary, Rikkunshito might prevent anorexia 
induced by cisplatin; thus, prophylactic administration was 
effective in chemotherapy with cisplatin, and patients could 
continue their treatment on schedule. This is the first report 
demonstrating the beneficial effects of Rikkunshito in the 
treatment of cisplatin therapy in humans. A   limitation of 
the present study is the small number of patients. It will 
be necessary to confirm the usefulness of Rikkunshito by 
  performing larger randomized controlled studies in the 
future.
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